CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

This juicy upside potential comes at a cost.

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

It has been about a month since the last earnings report for CRISPR Therapeutics AG (CRSP). Shares have added about 3.3% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...

Despite my optimism about the long-term prospects of curative gene therapy and CRISPR Therapeutics (NASDAQ:CRSP) stock, a sense of pragmatism and potentially a reality check are in order. Noting the ...

Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...

Right now marks an exciting moment for CRISPR Therapeutics (NASDAQ: CRSP) and its investors. The biotech company has reached three milestones in just a couple of months. First, back in November, the U ...

Crispr shares are trading higher Thursday after Wolfe Research initiated coverage on Crispr Therapeutics with a Peer Perform rating. Crispr Therapeutics' shares rise nearly 37% over the past month ...

Shares of gene therapy specialist, CRISPR Therapeutics (NASDAQ: CRSP) have been beaten down a long way despite some impressive accomplishments. The company already earned approval to sell its first ...